CSL to begin clinical trials for new immunoglobulin manufacturing process

• Horizon 2 is a patented process designed to increase yield and improve manufacturing efficiency for immunoglobulin, one of CSL's key products
• Clinical trials will begin in mid-2027 using material produced at CSL's Broadmeadows facility in Australia
• The initiative supports CSL's expansion plans, including increased manufacturing capacity for plasma-derived therapies in the United States over the next five years

Summary: CSL to Begin Clinical Trials for New Immunoglobulin Manufacturing Process

Key Developments:

Australian biotechnology company CSL announced on July 29 that it will commence clinical trials to support regulatory approval for an advanced immunoglobulin manufacturing process. The initiative aims to increase production yields from the same plasma volumes.

Technology and Timeline:

• The trials will test CSL's proprietary Horizon 2 technology, a patented process designed to boost yield and improve manufacturing efficiency for immunoglobulin, one of the company's core products
• Clinical work is scheduled to begin in mid-2027 using materials from CSL's Broadmeadows facility in Australia
• Studies will evaluate the safety and efficacy of immunoglobulin produced through this new method

Regulatory Pathway:

CSL has already engaged with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) regarding the trials, indicating a coordinated global regulatory approach.

Strategic Context:

In November, the Melbourne-based firm announced plans to expand its U.S. manufacturing footprint for plasma-derived therapies over the next five years, positioning this new process as part of a broader growth strategy.

Market Reaction:

CSL shares traded positively on the news, with the broader Australian market index rising 1.1%.

Implications:

The Horizon 2 technology could provide CSL with significant competitive advantages in immunoglobulin production by improving manufacturing efficiency without requiring additional plasma supply—a critical consideration given plasma sourcing constraints. Success in clinical trials and regulatory approval would strengthen CSL's position in the global plasma therapeutics market.